Figure 4.

Increased SIRT1 expression and decreased NF-κB-associated proinflammatory factor expression in some patients with GD after treatment. (A) The mRNA expression change of SIRT1 in PBMCs between pretherapy and posttreatment groups of GD patients. (B) The mRNA expression of TNF-α in patients with GD before and after treatment. (C) The mRNA expression change of IL-8 in PBMCs between pretherapy and posttreatment groups of GD patients. (D) The mRNA expression of MCP1 in patients with GD before and after treatment. (E) The mRNA expression change of IL-6 in PBMCs between pretherapy and posttreatment groups of GD patients. (F) Serum levels of TNF-α in patients with GD before and after treatment. (G) Serum levels of IL-6 in GD patients treated with and without anti-thyroid drugs. (H) Serum levels of IL-8 in GD patients treated with and without anti-thyroid drugs. (I) Serum levels of MCP1 in patients with GD before and after treatment. GD, Graves’ disease. Data represent means ± s.e.m. *P < 0.05, **P < 0.01, ***P < 0.001.